CPHI Milan newsletter
PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

CDMO Subsection

Insights into the latest developments in CDMO services and manufacturing.

Continue reading

Injectables Subsection

Expert perspectives on the evolving needs of injectable therapies and packaging.

Continue reading

Nasal & Pulmonary Subsection

Exploring the latest developments in inhalation technologies, respiratory delivery and sustainability

Continue reading

Advertisement

CPHI Milan
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Lifecore Biomedical

Advertisement

Solstice

The EU Unitary Patent – Overview and Practical Considerations

The preparations have spanned almost 40 years, and there have been many significant obstacles to overcome. However, the “Unitary Patent” and the dedicated “Unitary Patent Court (UPC)”are now an inevitability. Jon Gowshall and Charlotte Fox of Forresters give an overview of the new system and look at some of the practical implications of the Unitary Patent and UPC for patent owners. The UPC agreement was signed on 19 February 2013, and will come into force as soon as it has been ratified by enough countries (thirteen including the UK, Germany, and France), probably in 2015.
https://international-pharma.com/wp-content/uploads/2014/07/EU.pdf

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Tjoapack
Aptar – 08/01/2026